The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Andrea R. Hagemann
No relevant relationships to disclose
Israel Zighelboim
Research Funding - Genentech
Akiva Pesach Novetsky
No relevant relationships to disclose
Feng Gao
No relevant relationships to disclose
L. Stewart Massad
No relevant relationships to disclose
Premal H. Thaker
No relevant relationships to disclose
Matthew A. Powell
Honoraria - Genentech
Research Funding - Genentech; Lilly
David Gardner Mutch
Research Funding - Genentech
Jason D. Wright
Research Funding - Genentech